论文部分内容阅读
目的观察β受体阻滞剂卡维地洛对慢性充血性心力衰竭(CHF)的疗效。方法将慢性CHFl68例随机分为观察组和对照组,二组年龄、心力衰竭(心衰)病程、原发病及心功能分级相似,具可比性,二组均给予常规抗心衰治疗,观察组加用卡维地洛片剂,从小剂量2.5mg/d开始,3~5d递增2.5mg,直至病情改善或剂量为10mg/次,2次/d。观察治疗12周后二组患者的NYHA心功能分级、左室射血分数、心排血指数、血压、心率、病死率及副作用等。结果观察组较对照组NYHA心功能分级、左室射血分数、心排血指数均明显改善,血压、心率均明显降低,病死率下降,P<0.05或<0.01。结论在常规抗心衰治疗的基础上加用卡维地洛治疗慢性CHF,可明显改善患者心脏功能,提高患者生存率,且副作用小,值得临床推荐使用。
Objective To observe the effect of β-blocker carvedilol on chronic congestive heart failure (CHF). Methods Chronic CHF168 cases were randomly divided into observation group and control group, two groups of age, heart failure (heart failure) course, primary disease and cardiac function similar, comparable, two groups were given conventional anti-heart failure treatment, observation Group with carvedilol tablets, starting from a small dose of 2.5mg / d, 3 ~ 5d increased 2.5mg, until the condition improved or the dose of 10mg / time, 2 times / d. NYHA functional class, left ventricular ejection fraction, cardiac output index, blood pressure, heart rate, fatality rate and side effects were observed in the two groups after 12 weeks of treatment. Results Compared with the control group, the NYHA functional class, the left ventricular ejection fraction and the cardiac output index of the observation group were significantly improved, the blood pressure and heart rate were significantly decreased, and the mortality was decreased, P <0.05 or <0.01. Conclusions The use of carvedilol in the treatment of chronic CHF on the basis of conventional anti-heart failure treatment can significantly improve the cardiac function and improve the survival rate of patients with less side effects and is worthy of clinical recommendation.